Abbvie Inc.

Abbvic Inc.

Abbvie Ireland Unlimited Company

Barry M Bernstein

Sandeep Dutta

Walid M Awni

Sven Mensing

Rajeev M Menon

Thomas J Podsadecki

Daniel E Cohen

Cheri E Klein

Emily O Dumas

Amit Khatri

Scott C Brun

Wei Liu

Tianli Wang

Chih-Wei Lin

Andrew L Campbell

Tami J Pilot-Matias

Christine Ann Collins

Isabelle A Gaultier

Rakesh L Tripathi

The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

Methods for treating HCV

Method for treating HCV

The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.

The present invention features methods of using Compound I to suppress HCV mutants, treat treatment-experienced HCV patients, and treat HCV patients having non-CC IL28B rs12979860 genotype.

Compositions and methods for treating HCV

The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).

Growing community of inventors

Mequon, WI, United States of America

Barry M Bernstein